SCILEX HOLDING COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7454 USD | -10.21% |
|
-13.33% | -63.46% |
| 16/04 | Scilex Issues Preliminary Q1 Sales Results for ZTlido | MT |
| 20/03 | Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 564 | 199.6 | 90.28 | - | - |
| Enterprise Value (EV) 1 | 564 | 199.6 | 90.28 | 90.28 | 90.28 |
| P/E ratio | -23.5 x | -1.59 x | -2.19 x | -3.19 x | -3.73 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 4.27 x | 0.94 x | 0.66 x | 0.74 x |
| EV / Revenue | - | 4.27 x | 0.94 x | 0.66 x | 0.74 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -0.82 x | -1 x | -2.24 x |
| FCF Yield | - | - | -122% | -99.7% | -44.6% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,41,349 | 97,837 | 1,21,121 | - | - |
| Reference price 2 | 3.990 | 2.040 | 0.7454 | 0.7454 | 0.7454 |
| Announcement Date | 07/03/23 | 12/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 46.74 | 95.68 | 137.6 | 121.3 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -105.4 | -57.65 | -52.42 | -53 |
| Operating Margin | - | -225.55% | -60.25% | -38.08% | -43.69% |
| Earnings before Tax (EBT) 1 | - | -114.3 | -59.93 | -47.05 | -53 |
| Net income 1 | -23.36 | -114.3 | -59.93 | -47.05 | -58.3 |
| Net margin | - | -244.59% | -62.64% | -34.18% | -48.06% |
| EPS 2 | -0.1700 | -1.280 | -0.3400 | -0.2333 | -0.2000 |
| Free Cash Flow 1 | - | - | -109.7 | -90 | -40.3 |
| FCF margin | - | - | -114.65% | -65.39% | -33.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 07/03/23 | 12/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.12 | 13.46 | 17.75 | 23.18 | 25.34 | 29.4 | 35 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -38.8 | -18.34 | -13.92 | -9.869 | -11.15 | -9.106 | - |
| Operating Margin | - | -383.56% | -136.23% | -78.43% | -42.58% | -44.01% | -30.97% | - |
| Earnings before Tax (EBT) 1 | - | -35.53 | -21.39 | -15.72 | -11.26 | -12.1 | -9.536 | - |
| Net income 1 | -26.65 | -35.53 | -21.39 | -15.72 | -11.26 | -12.1 | -9.536 | - |
| Net margin | - | -351.18% | -158.87% | -88.57% | -48.58% | -47.76% | -32.43% | - |
| EPS 2 | -0.1900 | -0.6300 | -0.2500 | -0.1000 | -0.0850 | -0.0900 | -0.0700 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/08/23 | 14/11/23 | 12/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -110 | -90 | -40.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 07/03/23 | 12/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7454
USD
Average target price
5.5
USD
Spread / Average Target
+637.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.46% | 90.28M | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| +20.84% | 2.42B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B |
- Stock Market
- Equities
- SCLX Stock
- Financials Scilex Holding Company